Back to results
US 8,013,152 B2Granted
Biphenyl compounds useful as muscarinic receptor antagonists
AssigneeTheravance, Inc.
InventorsYuHua Ji, Mathai Mammen, Craig Husfeld, Li Li, YongQi Mu, Aaron Kushner, Eric Stangeland, Trevor Mischki, Adam Hughes, Sarah Dunham
Life of this patent
Estimating the term…
Abstract
The invention provides compounds of formula I: wherein a, b, c, m, s, t, W, Z, Ar, R1, R2, R3, R6, and R7 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Claims19
A compound of formula I:
- wherein:
- a is 0 or an integer of from 1 to 5;
- each R1 is independently selected from —C1-5alkyl, —C2-5alkenyl, —C2-5alkynyl, —C3-6cycloalkyl, -cyano, -halo, —OR1a, —C(O)OR1b, —SR1c, —S(O)R1d, —S(O)2R1e, —NR1fR1g, —NR1hS(O)2R1i, and —NR1jC(O)R1k;
- where each of R1a-1k is independently —H, —C1-5alkyl or phenyl-C1-5alkyl;
- b is 0 or an integer of from 1 to 4;
- each R2 is independently selected from —C1-5alkyl, —C2-5alkenyl, —C2-5alkynyl, —C3-6cycloalkyl, -cyano, -halo, —OR2a, —C(O)OR2b, —SR2c, —S(O)R2d, —S(O)2R2e, —NR2fR2g, —NR2hS(O)2R2i, and —NR2jC(O)R2k;
- where each of R2a-2k is independently —H, —C1-5alkyl or -phenyl-C1-5alkyl;
- W is —O— or —NWa—, where Wa is —H or —C1-5alkyl;
- c is 0 or an integer from 1 to 5;
- each R3 independently is —C1-5alkyl or two R3 groups are joined to form C1-3alkylene, C2-3alkenylene or oxiran-2,3-diyl;
- m is 0 or 1;
- Z is selected from —C(O)N(R4)— and —N(R4)C(O)—, where R4 is selected from —H, —C1-5alkyl, and —C3-5cycloalkyl;
- s is 0, 1 or 2;
- Ar is a phenylene substituted with (R5)q where q is 0 or an integer from 1 to 4 and each R5 is independently selected from -halo, —OH, —C1-5alkyl, and —C1-5alkoxy;
- t is 0, 1 or 2;
- R6 and R7 are taken together to form:
- or
- optionally substituted with one to three —C1-5alkyl groups, or
- where:
- d is 1 or 2;
- e is 0, 1 or 2;
- f is 0, 1, 2 or 3;
- R8 is selected from —C1-5alkyl and ═O;
- R9 is selected from —H, —C1-5alkyl, hydroxyphenyl, heteroaryl, and —X9R9a;
- where X9 is selected from —C1-5alkylene, —C(O)—, —C1-5alkylene-C(O)—, —C(O)—C1-5alkylene, —S(O2)—, —C1-5alkylene-S(O2)—, and —S(O2)—C1-5alkylene;
- and R9a is selected from —H, —OH, —C1-5alkyl, —C1-5alkoxy, aryl, heteroaryl, heterocyclyl, and —NR9bR9c, where R9b and R9c are independently —H or —C1-5alkyl;
- wherein each alkyl and alkoxy group in R1, R1a-1k, R2, R2a-2k, R5, R8, R9, and R9a-c is optionally substituted with 1 to 5 fluoro substituents;
- or a pharmaceutically acceptable salt or stereoisomer thereof.
25 more elements
Dependencies are inferred from the claim text.